Computational prediction of disease microRNAs in domestic animals

BMC Research Notes

Daniel G Peterson¹  Hui Wang¹  Mark Arick¹  Teresia Buza¹ 

[1] Institute for Genomics, Biocomputing & Biotechnology, Mississippi State University, P. O. Box 9627, Mississippi State 39762, USA

关键词: Phylogenetic analysis;    Orthology;    Homology;    Domestic animals;    Target;    Disease microRNAs;   

Others  :  826419
DOI  :  10.1186/1756-0500-7-403

 received in 2014-06-13, accepted in 2014-06-20,  发布年份 2014

【 摘 要 】

Background

The most important means of identifying diseases before symptoms appear is through the discovery of disease-associated biomarkers. Recently, microRNAs (miRNAs) have become highly useful biomarkers of infectious, genetic and metabolic diseases in human but they have not been well studied in domestic animals. It is probable that many of the animal homologs of human disease-associated miRNAs may be involved in domestic animal diseases. Here we describe a computational biology study in which human disease miRNAs were utilized to predict orthologous miRNAs in cow, chicken, pig, horse, and dog.

Results

We identified 287 human disease-associated miRNAs which had at least one 100% identical animal homolog. The 287 miRNAs were associated with 359 human diseases referenced in 2,863 Pubmed articles. Multiple sequence analysis indicated that over 60% of known horse mature miRNAs found perfect matches in human disease-associated miRNAs, followed by dog (50%). As expected, chicken had the least number of perfect matches (5%). Phylogenetic analysis of miRNA precursors indicated that 85% of human disease pre-miRNAs were highly conserved in animals, showing less than 5% nucleotide substitution rates over evolutionary time. As an example we demonstrated conservation of human hsa-miR-143-3p which is associated with type 2 diabetes and targets AKT1 gene which is highly conserved in pig, horse and dog. Functional analysis of AKT1 gene using Gene Ontology (GO) showed that it is involved in glucose homeostasis, positive regulation of glucose import, positive regulation of glycogen biosynthetic process, glucose transport and response to food.

Conclusions

This data provides the animal and veterinary research community with a resource to assist in generating hypothesis-driven research for discovering animal disease-related miRNA from their datasets and expedite development of prophylactic and disease-treatment strategies and also influence research efforts to identify novel disease models in large animals. Integrated data is available for download at http://agbase.hpc.msstate.edu/cgi-bin/animal_mirna.cgi webcite.

【 授权许可】

   
2014 Buza et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

【 参考文献 】

• [1]Winter J, Jung S, Keller S, Gregory RI, Diederichs S: Many roads to maturity: microRNA biogenesis pathways and their regulation. Nat Cell Biol 2009, 11(3):228-234.
• [2]Minguzzi S, Selcuklu SD, Spillane C, Parle-McDermott A: An NTD-Associated Polymorphism in the 3′ UTR of MTHFD1L can Affect Disease Risk by Altering miRNA Binding. Hum Mutat 2014, 35(1):96-104.
• [3]Wang L, Liu W, Jiang W, Lin J, Jiang Y, Li B, Pang D: A miRNA binding site single-nucleotide polymorphism in the 3′-UTR region of the IL23R gene is associated with breast cancer. PLoS One 2012, 7(12):e49823.
• [4]Fang L, Du WW, Yang X, Chen K, Ghanekar A, Levy G, Yang W, Yee AJ, Lu WY, Xuan JW, Gao Z, Xie F, He C, Deng Z, Yang BB: Versican 3'-untranslated region (3'-UTR) functions as a ceRNA in inducing the development of hepatocellular carcinoma by regulating miRNA activity. FASEB J 2013, 27(3):907-919.
• [5]Marin RM, Voellmy F, von Erlach T, Vanicek J: Analysis of the accessibility of CLIP bound sites reveals that nucleation of the miRNA: mRNA pairing occurs preferentially at the 3′-end of the seed match. RNA 2012, 18(10):1760-1770.
• [6]Niwa R, Slack FJ: The evolution of animal microRNA function. Curr Opin Genet Dev 2007, 17(2):145-150.
• [7]Christodoulou F, Raible F, Tomer R, Simakov O, Trachana K, Klaus S, Snyman H, Hannon GJ, Bork P, Arendt D: Ancient animal microRNAs and the evolution of tissue identity. Nature 2010, 463(7284):1084-1088.
• [8]Ma ZL, Yang HY, Tien P: Progress of miRNA and its functions in eukaryotes. Yi Chuan 2003, 30(7):693-696.
• [9]Pasquinelli AE, Reinhart BJ, Slack F, Martindale MQ, Kuroda MI, Maller B, Hayward DC, Ball EE, Degnan B, Muller P, Spring J, Srinivasan A, Fishman M, Finnerty J, Corbo J, Levine M, Leahy P, Davidson E, Ruvkun G: Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000, 408(6808):86-89.
• [10]Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, Horvitz HR, Ruvkun G: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 2000, 403(6772):901-906.
• [11]Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75(5):843-854.
• [12]Wightman B, Ha I, Ruvkun G: Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 1993, 75(5):855-862.
• [13]Lu TX, Sherrill JD, Wen T, Plassard AJ, Besse JA, Abonia JP, Franciosi JP, Putnam PE, Eby M, Martin LJ, Aronow BJ, Rothenberg ME: MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. J Allergy Clin Immunol 2012, 129(4):1064-1075 e1069.
• [14]Heneghan HM, Miller N, Kelly R, Newell J, Kerin MJ: Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist 2010, 15(7):673-682.
• [15]Shi H, Xu J, Zhang G, Xu L, Li C, Wang L, Zhao Z, Jiang W, Guo Z, Li X: Walking the interactome to identify human miRNA-disease associations through the functional link between miRNA targets and disease genes. BMC Syst Biol 2013, 7:101.
• [16]Bhayani MK, Calin GA, Lai SY: Functional relevance of miRNA sequences in human disease. Mutat Res 2012, 731(1–2):14-19.
• [17]Zheng Z, Zeng Y, Huang H, Xu F: MicroRNA-132 may play a role in coexistence of depression and cardiovascular disease: a hypothesis. Med Sci Monit 2013, 19:438-443.
• [18]Wu C, Gong Y, Sun A, Zhang Y, Zhang C, Zhang W, Zhao G, Zou Y, Ge J: The human MTHFR rs4846049 polymorphism increases coronary heart disease risk through modifying miRNA binding. Nutr Metab Cardiovasc Dis 2013, 23(7):693-698.
• [19]Steinfeld I, Navon R, Ach R, Yakhini Z: miRNA target enrichment analysis reveals directly active miRNAs in health and disease. Nucleic Acids Res 2013, 41(3):e45.
• [20]Shrivastava S, Petrone J, Steele R, Lauer GM, Di Bisceglie AM, Ray RB: Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 2013, 58(3):863-871.
• [21]Shimizu C, Kim J, Stepanowsky P, Trinh C, Lau HD, Akers JC, Chen C, Kanegaye JT, Tremoulet A, Ohno-Machado L, Burns JC: Differential expression of miR-145 in children with Kawasaki disease. PLoS One 2013, 8(3):e58159.
• [22]Shapshak P: Molecule of the month: miRNA and Human Prion brain disease. Bioinformation 2013, 9(13):659-660.
• [23]Selth LA, Townley SL, Gillis JL, Tilley WD, Butler LM: Identification of prostate cancer-associated micrornas in circulation using a mouse model of disease. Methods Mol Biol 2013, 1024:235-246.
• [24]Qi J, Hou S, Zhang Q, Liao D, Wei L, Fang J, Zhou Y, Kijlstra A, Yang P: A functional variant of pre-miRNA-196a2 confers risk for Behcet’s disease but not for Vogt-Koyanagi-Harada syndrome or AAU in ankylosing spondylitis. Hum Genet 2013, 132(12):1395-1404.
• [25]Qabaja A, Alshalalfa M, Bismar TA, Alhajj R: Protein network-based Lasso regression model for the construction of disease-miRNA functional interactions. EURASIP J Bioinform Syst Biol 2013, 2013(1):3.
• [26]Patel V, Williams D, Hajarnis S, Hunter R, Pontoglio M, Somlo S, Igarashi P: miR-17~92 miRNA cluster promotes kidney cyst growth in polycystic kidney disease. Proc Natl Acad Sci U S A 2013, 110(26):10765-10770.
• [27]Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, Goel A: Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg 2014, 259(4):735-743.
• [28]Hussein F-K, Nizar B, Mehdi N, Philippe L, Mohammad F-K, Rabih B, Eva H, Ahmad D, Nader H, Rim ED, Fadwa B, Luc V, Arsène B, Philippe M, Redouane R, Bassam B: Circulating miR-150 and miR-342 in plasma are novel potential biomarkers for acute myeloid leukemia. J Transl Med 2013, 11:31-31.
• [29]Erener S, Mojibian M, Fox JK, Denroche HC, Kieffer TJ: Circulating miR-375 as a biomarker of β-cell death and diabetes in mice. Endocrinology 2013, 154(2):603-608.
• [30]Zeng X, Xiang J, Wu M, Xiong W, Tang H, Deng M, Li X, Liao Q, Su B, Luo Z, Zhou Y, Zhou M, Zeng Z, Li X, Shen S, Shuai C, Li G, Fang J, Peng S: Circulating miR-17, miR-20a, miR-29c, and miR-223 combined as non-invasive biomarkers in nasopharyngeal carcinoma. PLoS One 2012, 7(10):e46367.
• [31]Wang N, Zhou Y, Jiang L, Li D, Yang J, Zhang CY, Zen K: Urinary microRNA-10a and microRNA-30d serve as novel, sensitive and specific biomarkers for kidney injury. PLoS One 2012, 7(12):e51140.
• [32]Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, Li J: Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One 2012, 7(10):e47003.
• [33]Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon Y-J, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM: EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med 2012, 18(1):74-82.
• [34]Tsujiura M, Ichikawa D, Komatsu S, Shiozaki A, Takeshita H, Kosuga T, Konishi H, Morimura R, Deguchi K, Fujiwara H, Okamoto K, Otsuji E: Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010, 102(7):1174-1179.
• [35]Zeng Z, Wang J, Zhao L, Hu P, Zhang H, Tang X, He D, Tang S, Zeng Z: Potential role of microRNA-21 in the diagnosis of gastric cancer: a meta-analysis. PLoS One 2013, 8(9):e73278.
• [36]Zeng R-C, Zhang W, Yan X-Q, Ye Z-Q, Chen E-D, Huang D-P, Zhang X-H, Huang G-L: Down-regulation of miRNA-30a in human plasma is a novel marker for breast cancer. Med Oncol 2013, 30(1):477.
• [37]Yong FL, Law CW, Wang CW: Potentiality of a triple microRNA classifier: miR-193a-3p, miR-23a and miR-338-5p for early detection of colorectal cancer. BMC Cancer 2013, 13:280-280.
• [38]Ye J, Wu X, Wu D, Wu P, Ni C, Zhang Z, Chen Z, Qiu F, Xu J, Huang J: miRNA-27b targets vascular endothelial growth factor C to inhibit tumor progression and angiogenesis in colorectal cancer. PLoS One 2013, 8(4):e60687.
• [39]Wu J, Yang T, Li X, Yang Q, Liu R, Huang J, Li Y, Yang C, Jiang Y: Alteration of serum miR-206 and miR-133b is associated with lung carcinogenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Toxicol Appl Pharmacol 2013, 267(3):238-246.
• [40]Yamada N, Nakagawa Y, Tsujimura N, Kumazaki M, Noguchi S, Mori T, Hirata I, Maruo K, Akao Y: Role of intracellular and extracellular MicroRNA-92a in colorectal cancer. Transl Oncol 2013, 6(4):482-492.
• [41]Watahiki A, Macfarlane RJ, Gleave ME, Crea F, Wang Y, Helgason CD, Chi KN: Plasma miRNAs as biomarkers to identify patients with castration-resistant metastatic prostate cancer. Int J Mol Sci 2013, 14(4):7757-7770.
• [42]Wang Z, Han J, Cui Y, Fan K, Zhou X: Circulating microRNA-21 as noninvasive predictive biomarker for response in cancer immunotherapy. Med Hypotheses 2013, 81(1):41-43.
• [43]Wang JL, Hu Y, Kong X, Wang ZH, Chen HY, Xu J, Fang JY: Candidate microRNA biomarkers in human gastric cancer: a systematic review and validation study. PLoS One 2013, 8(9):e73683.
• [44]Gidlöf O, Smith JG, Miyazu K, Gilje P, Spencer A, Blomquist S, Erlinge D: Circulating cardio-enriched microRNAs are associated with long-term prognosis following myocardial infarction. BMC Cardiovasc Disord 2013, 13:12-12.
• [45]Zhu S, Cao L, Zhu J, Kong L, Jin J, Qian L, Zhu C, Hu X, Li M, Guo X, Han S, Yu Z: Identification of maternal serum microRNAs as novel non-invasive biomarkers for prenatal detection of fetal congenital heart defects. Clin Chim Acta 2013, 424:66-72.
• [46]Zhou X, Mao A, Wang X, Duan X, Yao Y, Zhang C: Urine and serum microRNA-1 as novel biomarkers for myocardial injury in open-heart surgeries with cardiopulmonary bypass. PLoS One 2013, 8(4):e62245.
• [47]Wang E, Nie Y, Zhao Q, Wang W, Huang J, Liao Z, Zhang H, Hu S, Zheng Z: Circulating miRNAs reflect early myocardial injury and recovery after heart transplantation. J Cardiothorac Surg 2013, 8:165-165.
• [48]Matsumoto S, Sakata Y, Suna S, Nakatani D, Usami M, Hara M, Kitamura T, Hamasaki T, Nanto S, Kawahara Y, Komuro I: Circulating p53-responsive microRNAs are predictive indicators of heart failure after acute myocardial infarction. Circ Res 2013, 113(3):322-326.
• [49]Finn NA, Eapen D, Manocha P, Al Kassem H, Lassegue B, Ghasemzadeh N, Quyyumi A, Searles CD: Coronary heart disease alters intercellular communication by modifying microparticle-mediated microRNA transport. FEBS Lett 2013, 587(21):3456-3463.
• [50]Dickinson BA, Semus HM, Montgomery RL, Stack C, Latimer PA, Lewton SM, Lynch JM, Hullinger TG, Seto AG, van Rooij E: Plasma microRNAs serve as biomarkers of therapeutic efficacy and disease progression in hypertension-induced heart failure. Eur J Heart Fail 2013, 15(6):650-659.
• [51]Wang H, Lu H-M, Yang W-H, Luo C, Lu S-H, Zhou Y, Lin Y-Z: The influence of statin therapy on circulating microRNA-92a expression in patients with coronary heart disease. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2012, 24(4):215-218.
• [52]Agarwal SM, Raghav D, Singh H, Raghava GP: CCDB: a curated database of genes involved in cervix cancer. Nucleic Acids Res 2011, 39(Database issue):D975-979.
• [53]Gong J, Tong Y, Zhang HM, Wang K, Hu T, Shan G, Sun J, Guo AY: Genome-wide identification of SNPs in microRNA genes and the SNP effects on microRNA target binding and biogenesis. Hum Mutat 2012, 33(1):254-263.
• [54]Guo D, Liu J, Wang W, Hao F, Sun X, Wu X, Bu P, Zhang Y, Liu Y, Liu F, Zhang Q, Jiang F: Alteration in abundance and compartmentalization of inflammation-related miRNAs in plasma after intracerebral hemorrhage. Stroke 2013, 44(6):1739-1742.
• [55]Wang H, Peng W, Shen X, Huang Y, Ouyang X, Dai Y: Circulating levels of inflammation-associated miR-155 and endothelial-enriched miR-126 in patients with end-stage renal disease. Braz J Med Biol Res 2012, 45(12):1308-1314.
• [56]Bala S, Petrasek J, Mundkur S, Catalano D, Levin I, Ward J, Alao H, Kodys K, Szabo G: Circulating microRNAs in exosomes indicate hepatocyte injury and inflammation in alcoholic, drug-induced, and inflammatory liver diseases. Hepatology 2012, 56(5):1946-1957.
• [57]Bhattacharyya S, Balakathiresan NS, Dalgard C, Gutti U, Armistead D, Jozwik C, Srivastava M, Pollard HB, Biswas R: Elevated miR-155 promotes inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem 2011, 286(13):11604-11615.
• [58]Blanco-Calvo M, Calvo L, Figueroa A, Haz-Conde M, Antón-Aparicio L, Valladares-Ayerbes M: Circulating microRNAs: molecular microsensors in gastrointestinal cancer. Sensors (Basel) 2012, 12(7):9349-9362.
• [59]Barnard JA: Recent advances in pediatric gastroenterology, hepatology and nutrition. F1000Prime Rep 2013, 5:25.
• [60]Duttagupta R, DiRienzo S, Jiang R, Bowers J, Gollub J, Kao J, Kearney K, Rudolph D, Dawany NB, Showe MK, Stamato T, Getts RC, Jones KW: Genome-wide maps of circulating miRNA biomarkers for ulcerative colitis. PLoS One 2012, 7(2):e31241.
• [61]Li Y, Qiu C, Tu J, Geng B, Yang J, Jiang T, Cui Q: HMDD v2.0: a database for experimentally supported human microRNA and disease associations. Nucleic Acids Res 2014, 42(Database issue):D1070-1074.
• [62]Bhattacharya A, Ziebarth JD, Cui Y: PolymiRTS Database 3.0: linking polymorphisms in microRNAs and their target sites with human diseases and biological pathways. Nucleic Acids Res 2014, 42(Database issue):D86-91.
• [63]Dong L, Luo M, Wang F, Zhang J, Li T, Yu J: TUMIR: an experimentally supported database of microRNA deregulation in various cancers. J Clin Bioinformatics 2013, 3(1):7.
• [64]Bruno AE, Li L, Kalabus JL, Pan Y, Yu A, Hu Z: miRdSNP: a database of disease-associated SNPs and microRNA target sites on 3′UTRs of human genes. BMC Genomics 2012, 13:44.
• [65]Ruepp A, Kowarsch A, Theis F: PhenomiR: microRNAs in human diseases and biological processes. Methods Mol Biol 2012, 822:249-260.
• [66]Ziebarth JD, Bhattacharya A, Chen A, Cui Y: PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res 2012, 40(Database issue):D216-221.
• [67]Xie B, Ding Q, Han H, Wu D: miRCancer: a microRNA-cancer association database constructed by text mining on literature. Bioinformatics 2013, 29(5):638-644.
• [68]Kiran C, Deepika P: Lung cancer: microRNA and target database. Zhongguo Fei Ai Za Zhi 2012, 15(7):429-434.
• [69]Mitra S, Das S, Das S, Ghosal S, Chakrabarti J: HNOCDB: a comprehensive database of genes and miRNAs relevant to head and neck and oral cancer. Oral Oncol 2012, 48(2):117-119.
• [70]Yang Z, Ren F, Liu C, He S, Sun G, Gao Q, Yao L, Zhang Y, Miao R, Cao Y, Zhao Y, Zhong Y, Zhao H: dbDEMC: a database of differentially expressed miRNAs in human cancers. BMC Genomics 2010, 11 Suppl 4:S5.
• [71]Lu M, Zhang Q, Deng M, Miao J, Guo Y, Gao W, Cui Q: An analysis of human microRNA and disease associations. PLoS One 2008, 3(10):e3420.
• [72]Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, Li M, Wang G, Liu Y: miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res 2009, 37(Database issue):D98-104.
• [73]Kozomara A, Griffiths-Jones S: miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 2011, 39(Database issue):D152-157.
• [74]Sievers F, Wilm A, Dineen D, Gibson TJ, Karplus K, Li W, Lopez R, McWilliam H, Remmert M, Söding J, Thompson JD, Higgins DG: Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol 2011, 7:539.
• [75]EMBL-EBI: ClustalW2 – Phylogeny: commonly used phylogenetic tree generation methods provided by the ClustalW2 program. http://www.ebi.ac.uk/Tools/services/web/toolform.ebi?tool=clustalw2_phylogeny webcite
• [76]Kasprzyk A: BioMart: driving a paradigm change in biological data management. Database (Oxford) 2011, 2011:bar049.
• [77]Baxevanis AD: Searching Online Mendelian Inheritance in Man (OMIM) for information on genetic loci involved in human disease. Curr Protoc Hum Genet 2012, Chapter 9:Unit 9 13 11–10.
• [78]Lenffer J, Nicholas FW, Castle K, Rao A, Gregory S, Poidinger M, Mailman MD, Ranganathan S: OMIA (Online Mendelian Inheritance in Animals): an enhanced platform and integration into the Entrez search interface at NCBI. Nucleic Acids Res 2006, 34(Database issue):D599-601.
• [79]Schriml LM, Arze C, Nadendla S, Chang YW, Mazaitis M, Felix V, Feng G, Kibbe WA: Disease Ontology: a backbone for disease semantic integration. Nucleic Acids Res 2012, 40(Database issue):D940-946.
• [80]Smith B, Ashburner M, Rosse C, Bard J, Bug W, Ceusters W, Goldberg LJ, Eilbeck K, Ireland A, Mungall CJ, Leontis N, Rocca-Serra P, Ruttenberg A, Sansone SA, Scheuermann RH, Shah N, Whetzel PL, Lewis S, Consortium OBI: The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol 2007, 25(11):1251-1255.
• [81]Gremse M, Chang A, Schomburg I, Grote A, Scheer M, Ebeling C, Schomburg D: The BRENDA Tissue Ontology (BTO): the first all-integrating ontology of all organisms for enzyme sources. Nucleic Acids Res 2011, 39(Database issue):D507-513.
• [82]McCarthy FM, Gresham CR, Buza TJ, Chouvarine P, Pillai LR, Kumar R, Ozkan S, Wang H, Manda P, Arick T, Bridges SM, Burgess SC: AgBase: supporting functional modeling in agricultural organisms. Nucleic Acids Res 2011, 39(Database issue):D497-506.
• [83]McCarthy FM, Wang N, Magee GB, Nanduri B, Lawrence ML, Camon EB, Barrell DG, Hill DP, Dolan ME, Williams WP, Luthe DS, Bridges SM, Burgess SC: AgBase: a functional genomics resource for agriculture. BMC genomics 2006, 7:229.
• [84]Jordan SD, Kruger M, Willmes DM, Redemann N, Wunderlich FT, Bronneke HS, Merkwirth C, Kashkar H, Olkkonen VM, Bottger T, Braun T, Seibler J, Bruning JC: Obesity-induced overexpression of miRNA-143 inhibits insulin-stimulated AKT activation and impairs glucose metabolism. Nat Cell Biol 2011, 13(4):434-446.
• [85]Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, Foulger R, Eilbeck K, Lewis S, Marshall B, Mungall C, Richter J, Rubin GM, Blake JA, Bult C, Dolan M, Drabkin H, Eppig JT, Hill DP, Ni L, Ringwald M, Balakrishnan R, Cherry JM, Christie KR, Costanzo MC, Dwight SS, Engel S, Fisk DG, Hirschman JE, Hong EL, Nash RS, et al.: The Gene Ontology (GO) database and informatics resource. Nucleic Acids Res 2004, 32(Database issue):D258-261.
• [86]Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G: Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 2000, 25(1):25-29.
• [87]Zhao A, Li G, Peoc’h M, Genin C, Gigante M: Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp Mol Pathol 2013, 94(1):115-120.
• [88]Yu X, Luo L, Wu Y, Yu X, Liu Y, Yu X, Zhao X, Zhang X, Cui L, Ye G, Le Y, Guo J: Gastric juice miR-129 as a potential biomarker for screening gastric cancer. Med Oncol 2013, 30(1):365.
• [89]Yang IP, Tsai H-L, Huang C-W, Huang M-Y, Hou M-F, Juo S-HH, Wang J-Y: The functional significance of MicroRNA-29c in patients with colorectal cancer: a potential circulating biomarker for predicting early relapse. PLoS One 2013., 8(6)
• [90]Ting HJ, Messing J, Yasmin-Karim S, Lee YF: Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D. J Biol Chem 2013, 288(1):1-9.
• [91]Si H, Sun X, Chen Y, Cao Y, Chen S, Wang H, Hu C: Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol 2013, 139(2):223-229.
• [92]Mori F, Strano S, Blandino G: MicroRNA-181a/b: novel biomarkers to stratify breast cancer patients for PARPi treatment. Cell Cycle 2013, 12(12):1823-1824.
• [93]Li C, Li JF, Cai Q, Qiu QQ, Yan M, Liu BY, Zhu ZG: MiRNA-199a-3p: A potential circulating diagnostic biomarker for early gastric cancer. J Surg Oncol 2013, 108(2):89-92.
• [94]Endo K, Naito Y, Ji X, Nakanishi M, Noguchi T, Goto Y, Nonogi H, Ma X, Weng H, Hirokawa G, Asada T, Kakinoki S, Yamaoka T, Fukushima Y, Iwai N: MicroRNA 210 as a biomarker for congestive heart failure. Biol Pharm Bull 2013, 36(1):48-54.
• [95]Bauters C, Kumarswamy R, Holzmann A, Bretthauer J, Anker SD, Pinet F, Thum T: Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int J Cardiol 2013, 168(3):1837-1840.
• [96]Parker HG, Ostrander EA: Cancer. Hiding in plain view--an ancient dog in the modern world. Science 2014, 343(6169):376-378.
• [97]Rowell JL, McCarthy DO, Alvarez CE: Dog models of naturally occurring cancer. Trends Mol Med 2011, 17(7):380-388.
• [98]Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L, Breen M, Kitchell B, McNeil E, Modiano JF, Niemi S, Comstock KE, Ostrander E, Westmoreland S, Withrow S: The dog as a cancer model. Nat Biotechnol 2006, 24(9):1065-1066.
• [99]Davis JL, Gardner SY, Schwabenton B, Breuhaus BA: Congestive heart failure in horses: 14 cases (1984–2001). J Am Vet Med Assoc 2002, 220(10):1512-1515.